An open clinical study of Camrelizumab combined with radiotherapy in the treatment of advanced non-small cell lung cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039895

Enrollment

Unknown

Registered

2020-11-13

Start date

2020-11-18

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small cell lung cancer

Interventions

Experimental group:Camrelizumab combined with radiotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Patients must voluntarily participate in this study and sign the informed consent; 2.Histologically confirmed patients with advanced non-small cell lung cancer; 3.Aged >= 18 years; 4.Measurable tumor lesions according to RECIST 1.1; 5.ECOG PS: 0-2 marks; 6.Function of vital organs is normal; 7.Expected survival >= 3 months; 8.No positive EGFR or ALK mutation.

Exclusion criteria

Exclusion criteria: 1.Previous or concurrent malignancies, except adequately treated non-melanoma skin cancer, cervical carcinoma in situ and thyroid papillary carcinoma; 2.Patients who have already started radiotherapy and patients who are highly allergic to any study drug or excipient; 3.Active tuberculosis infection; 4.Patients who have an active, known or suspected autoimmune disease (including but not limited to: uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, vasculitis, hyperthyroidism, hypothyroidism, and asthma requiring bronchodilator treatment). Subjects with hypothyroidism that require only hormone replacement therapy and skin disorders that require no systemic treatment (such as vitiligo, psoriasis, or alopecia) are eligible for inclusion; 5.Within 6 months before entering the study, the following conditions occurred: myocardial infarction, severe/unstable angina pectoris, NYHA grade 2 or above cardiac dysfunction, and poorly controlled arrhythmia (including QTcF interphase male & GT; 450 ms, Female & GT; 470 ms, QTcF interval calculated by the Fridericia formula), symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism); 6.Patients receiving hematopoietic stem cells or organ transplants; 7.Human immunodeficiency virus (HIV, HIV 1/2 antibody) positive; 8.A history of psychotropic substance abuse, alcohol abuse or drug abuse; 9. Pregnant or lactating women; 10.The researcher believes that it is inappropriate to participate in this trial.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Secondary

Measure	Time frame
ORR;DCR;OS;	—

Countries

China

Contacts

Public ContactSongliu Hu

Affiliated Cancer Hospital of Harbin Medical University

husongliu@126.com+86 13654619245

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026